Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib + Tislelizumab in Advanced Solid Tumors
NCT03666143Phase 1Completed
- Sponsor
- BeiGene
- Start
- Nov 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sitravatinib in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer and 1 more, sponsored by BeiGene. Primary endpoint: Number of Participants With Adverse Events. Started Nov 2018; status: completed.
02
Drugs
sitravatinib
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)ovarian cancermelanoma
Beyond the preview
Go deeper on NCT03666143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666143.